Literature DB >> 29296933

Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia.

Ross Kinstrie1, Dimitris Karamitros2,3, Nicolas Goardon2,3, Heather Morrison1, Mike Hamblin4, Lisa Robinson5, Richard E Clark6, Mhairi Copland1, Paresh Vyas2,3,7.   

Abstract

Chronic myeloid leukemia (CML) is an excellent model of the multistep processes in cancer. Initiating BCR-ABL mutations are required for the initial phase of the disease (chronic phase, CP-CML). Some CP-CML patients acquire additional mutation(s) that transforms CP-CML to poor prognosis, hard to treat, acute myeloid or lymphoid leukemia or blast phase CML (BP-CML). It is unclear where in the hemopoietic hierarchy additional mutations are acquired in BP-CML, how the hemopoietic hierarchy is altered as a consequence, and the cellular identity of the resulting leukemia-propagating stem cell (LSC) populations. Here, we show that myeloid BP-CML is associated with expanded populations that have the immunophenotype of normal progenitor populations that vary between patients. Serial transplantation in immunodeficient mice demonstrated functional LSCs reside in multiple populations with the immunophenotype of normal progenitor as well as stem cells. Multicolor fluorescence in situ hybridization detected serial acquisition of cytogenetic abnormalities of chromosome 17, associated with transformation to BP-CML, that is detected with equal frequency in all functional LSC compartments. New effective myeloid BP-CML therapies will likely have to target all these LSC populations.

Entities:  

Year:  2016        PMID: 29296933      PMCID: PMC5737170          DOI: 10.1182/bloodadvances.2016000810

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  17 in total

1.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.

Authors:  Catriona H M Jamieson; Laurie E Ailles; Scott J Dylla; Manja Muijtjens; Carol Jones; James L Zehnder; Jason Gotlib; Kevin Li; Markus G Manz; Armand Keating; Charles L Sawyers; Irving L Weissman
Journal:  N Engl J Med       Date:  2004-08-12       Impact factor: 91.245

2.  Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.

Authors:  Max Jan; Thomas M Snyder; M Ryan Corces-Zimmerman; Paresh Vyas; Irving L Weissman; Stephen R Quake; Ravindra Majeti
Journal:  Sci Transl Med       Date:  2012-08-29       Impact factor: 17.956

3.  Functional heterogeneity of genetically defined subclones in acute myeloid leukemia.

Authors:  Jeffery M Klco; David H Spencer; Christopher A Miller; Malachi Griffith; Tamara L Lamprecht; Michelle O'Laughlin; Catrina Fronick; Vincent Magrini; Ryan T Demeter; Robert S Fulton; William C Eades; Daniel C Link; Timothy A Graubert; Matthew J Walter; Elaine R Mardis; John F Dipersio; Richard K Wilson; Timothy J Ley
Journal:  Cancer Cell       Date:  2014-03-06       Impact factor: 31.743

4.  Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.

Authors:  Simona Soverini; Sabrina Colarossi; Alessandra Gnani; Gianantonio Rosti; Fausto Castagnetti; Angela Poerio; Ilaria Iacobucci; Marilina Amabile; Elisabetta Abruzzese; Ester Orlandi; Franca Radaelli; Fabrizio Ciccone; Mario Tiribelli; Roberto di Lorenzo; Clementina Caracciolo; Barbara Izzo; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani; Giovanni Martinelli
Journal:  Clin Cancer Res       Date:  2006-12-15       Impact factor: 12.531

5.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

6.  Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.

Authors:  T Holyoake; X Jiang; C Eaves; A Eaves
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

7.  How I treat CML blast crisis.

Authors:  Rüdiger Hehlmann
Journal:  Blood       Date:  2012-05-31       Impact factor: 22.113

8.  Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.

Authors:  M Ryan Corces-Zimmerman; Wan-Jen Hong; Irving L Weissman; Bruno C Medeiros; Ravindra Majeti
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

9.  Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Authors:  Petter S Woll; Una Kjällquist; Onima Chowdhury; Helen Doolittle; David C Wedge; Supat Thongjuea; Rikard Erlandsson; Mtakai Ngara; Kristina Anderson; Qiaolin Deng; Adam J Mead; Laura Stenson; Alice Giustacchini; Sara Duarte; Eleni Giannoulatou; Stephen Taylor; Mohsen Karimi; Christian Scharenberg; Teresa Mortera-Blanco; Iain C Macaulay; Sally-Ann Clark; Ingunn Dybedal; Dag Josefsen; Pierre Fenaux; Peter Hokland; Mette S Holm; Mario Cazzola; Luca Malcovati; Sudhir Tauro; David Bowen; Jacqueline Boultwood; Andrea Pellagatti; John E Pimanda; Ashwin Unnikrishnan; Paresh Vyas; Gudrun Göhring; Brigitte Schlegelberger; Magnus Tobiasson; Gunnar Kvalheim; Stefan N Constantinescu; Claus Nerlov; Lars Nilsson; Peter J Campbell; Rickard Sandberg; Elli Papaemmanuil; Eva Hellström-Lindberg; Sten Linnarsson; Sten Eirik W Jacobsen
Journal:  Cancer Cell       Date:  2014-05-15       Impact factor: 31.743

10.  Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.

Authors:  Lynn Quek; Georg W Otto; Catherine Garnett; Ludovic Lhermitte; Dimitris Karamitros; Bilyana Stoilova; I-Jun Lau; Jessica Doondeea; Batchimeg Usukhbayar; Alison Kennedy; Marlen Metzner; Nicolas Goardon; Adam Ivey; Christopher Allen; Rosemary Gale; Benjamin Davies; Alexander Sternberg; Sally Killick; Hannah Hunter; Paul Cahalin; Andrew Price; Andrew Carr; Mike Griffiths; Paul Virgo; Stephen Mackinnon; David Grimwade; Sylvie Freeman; Nigel Russell; Charles Craddock; Adam Mead; Andrew Peniket; Catherine Porcher; Paresh Vyas
Journal:  J Exp Med       Date:  2016-07-04       Impact factor: 14.307

View more
  2 in total

1.  A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.

Authors:  T L Holyoake; M Copland; G A Horne; J Stobo; C Kelly; A Mukhopadhyay; A L Latif; J Dixon-Hughes; L McMahon; P Cony-Makhoul; J Byrne; G Smith; S Koschmieder; T H BrÜmmendorf; P Schafhausen; P Gallipoli; F Thomson; W Cong; R E Clark; D Milojkovic; G V Helgason; L Foroni; F E Nicolini
Journal:  Leukemia       Date:  2020-01-10       Impact factor: 11.528

Review 2.  Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.

Authors:  Fabien Muselli; Jean-François Peyron; Didier Mary
Journal:  Int J Mol Sci       Date:  2019-11-10       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.